Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
-1.26%-1.44%+0.77%+6.10% 50.35B
-1.72%-5.10%+372.34%+581.62% 39.21B
+2.02%+1.03%+33.08%-4.63% 34.52B
+2.78%+6.14%+15.14%+62.41% 34.6B
+1.68%-0.62%+3.30%+27.34% 27.05B
-1.37%-3.20% - - 16.68B
+0.91%+0.01%+70.10%+116.50% 15.11B
-0.23%+0.52%+14.39%+17.74% 13.85B
-0.06%+2.06%+19.59%-29.70% 13.18B
Average +0.84%+0.94%+66.09%+97.17% 27.17B
Weighted average by Cap. +0.29%+0.83%+78.60%+120.54%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-